Home > Journals > Minerva Cardioangiologica > Past Issues > Articles online first > Minerva Cardioangiologica 2016 Apr 27

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as

 

 

Minerva Cardioangiologica 2016 Apr 27

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis

Elena MEDVEDEVA 1, Ivan BEREZIN 1, Elena SURKOVA 1, 2, Dmitry YARANOV 3, Yuri SHCHUKIN 1

1 Department of Cardiology, Samara State Medical University, Samara, Russian Federation; 2 Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy; 3 Department of Internal Medicine, Danbury Hospital, Danbury, CT, USA


PDF


BACKGROUND: Galectin-3 is a recently developed biomarker of fibrosis, which may play a role in cardiac remodeling and associated with both the progression and severity of heart failure.
METHODS: A prospective cohort study of 190 patients with documented prior myocardial infarction and chronic HF (NYHA class II-IV) was conducted. Patients were divided into 3 groups based on their NYHA functional class. Levels of galectin-3, NT-proBNP, CRP, IL-6, oxidized-LDL, extracellular superoxide dismutase (EC-SOD), 3-nitrotyrosine, SH-groups, cystatin-C were determined. Follow-up period was 26 months, and all-cause mortality was determined as the primary end-point. Statistical analysis was performed and statistical significance was set at p<0.05.
RESULTS: The cytokines hs-CRP, IL-6 and markers of oxidative stress had significant positive correlation with plasma galectin-3 levels in all groups of patients. The level of galectin-3 was significantly different between the groups (p <0.05). Galectin-3 was found to be the most sensitive and specific value in determination of 26 months mortality in patients with chronic HF. Logistic regression analysis showed that age, galectin-3 and cystatin-C were associated with death during the follow up period.
CONCLUSIONS: Galectin-3 levels are elevated in patients with chronic HF across all NYHA functional classes. Galectin-3 shows positive correlation with markers of oxidative stress, inflammation and kidney dysfunction. Galectin-3 levels and cystatin-C levels are independent predictors of 26-month mortality in patients with chronic HF. Patients with cystatin-C level > 2800 pg/ml carry a worse prognosis. Galectin-3 level > 21 ng/ml associated with increased mortality.

top of page